Atrial natriuretic peptide - DRAXIMAGE

Drug Profile

Atrial natriuretic peptide - DRAXIMAGE

Alternative Names: Radiolabeled atrial natriuretic peptide

Latest Information Update: 12 Sep 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Clinical Research Institute of Montreal; Hotel Dieu de Montreal
  • Developer Clinical Research Institute of Montreal; DRAXIMAGE; Hotel Dieu de Montreal
  • Class Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Kidney disorders

Most Recent Events

  • 05 Oct 2001 Preclinical development for Kidney disorders (diagnosis) in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top